Seminal Trials Series: ECOG 1594

Nov 07, 2022
Episode
130
Share

At the time it was published in the New England Journal of Medicine in 2002, ECOG 1594 was the first study to compare whether any of the three chemotherapy regimens used at the time was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez interview the ECOG 1594 clinical trial investigators to learn just how important, and controversial, this study was. 

Guest
Stephen Liu
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Dr. Chandra Belani
Dr. Chandra Belani

MD

Deputy Director of Penn State Herschey Cancer Institute (PSCHI), and Miriam Beckner Distinguished Professor of Medicine
Penn State Hershey Medical Center & College of Medicine
Dr. Corey Langer
Dr. Corey Langer

MD

Director of Thoracic Oncology and Professor of Medicine
Hospital of the University of Pennsylvania
Dr. Alan Sandler
Dr. Alan Sandler

MD

President, Head of Global Development Oncology
Zai Lab
Joan Schiller
Dr. Joan Schiller

MD

Lung Cancer Research Foundation
Dr. Frances Shepherd
Dr. Frances Shepherd

MD

Senior Scientist & Clinical Investigator
Princess Margaret Cancer Centre, Cancer Clinical Research Unit (CCRU)

Other Podcast